Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

PICAROS - Acalabrutinib RWE på 1L CLL i Spanien (PICAROS)

3 november 2026 uppdaterad av: AstraZeneca

Icke-interventionell kohortstudie av patienter som tidigare inte behandlats eller första generationens BTKi-intoleranta med kronisk lymfatisk leukemi som beskriver förstahandsanvändningen av acalabrutinib och dess verkliga resultat i Spanien: PICAROS-studien

This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.

It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

Studietyp

Observationell

Inskrivning (Beräknad)

315

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Andalusia
      • Almería, Andalusia, Spanien, 4009
        • Rekrytering
        • Research Site
      • Córdoba, Andalusia, Spanien, 14004
        • Rekrytering
        • Research Site
      • Granada, Andalusia, Spanien, 18014
        • Rekrytering
        • Research Site
      • Jaén, Andalusia, Spanien, 23007
        • Aktiv, inte rekryterande
        • Research Site
      • Marbella, Andalusia, Spanien, 29603
        • Aktiv, inte rekryterande
        • Research Site
      • Málaga, Andalusia, Spanien, 29010
        • Aktiv, inte rekryterande
        • Research Site
      • Seville, Andalusia, Spanien, 41013
        • Rekrytering
        • Research Site
    • Aragon
      • Zaragoza, Aragon, Spanien, 50009
        • Rekrytering
        • Research Site
      • Zaragoza, Aragon, Spanien, 50009
        • Aktiv, inte rekryterande
        • Research Site
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, Spanien, 7010
        • Aktiv, inte rekryterande
        • Research Site
      • Palma de Mallorca, Balearic Islands, Spanien, 7198
        • Aktiv, inte rekryterande
        • Research Site
    • Basque Country
      • Donostia / San Sebastian, Basque Country, Spanien, 20014
        • Indragen
        • Research Site
      • Galdakao, Basque Country, Spanien, 48960
        • Indragen
        • Research Site
    • Canary Islands
      • Las Palmas de Gran Canaria, Canary Islands, Spanien, 35016
        • Aktiv, inte rekryterande
        • Research Site
      • Las Palmas de Gran Canaria, Canary Islands, Spanien, 35019
        • Aktiv, inte rekryterande
        • Research Site
      • San Cristóbal de La Laguna, Canary Islands, Spanien, 38320
        • Rekrytering
        • Research Site
    • Cantabria
      • Santander, Cantabria, Spanien, 39008
        • Aktiv, inte rekryterande
        • Research Site
    • Castille and León
      • Salamanca, Castille and León, Spanien, 37007
        • Aktiv, inte rekryterande
        • Research Site
      • Segovia, Castille and León, Spanien, 40002
        • Aktiv, inte rekryterande
        • Research Site
      • Valladolid, Castille and León, Spanien, 47003
        • Aktiv, inte rekryterande
        • Research Site
      • Valladolid, Castille and León, Spanien, 47012
        • Aktiv, inte rekryterande
        • Research Site
    • Castille-La Mancha
      • Guadalajara, Castille-La Mancha, Spanien, 19002
        • Rekrytering
        • Research Site
      • Toledo, Castille-La Mancha, Spanien, 45004
        • Aktiv, inte rekryterande
        • Research Site
    • Catalonia
      • Barcelona, Catalonia, Spanien, 8003
        • Aktiv, inte rekryterande
        • Research Site
      • Barcelona, Catalonia, Spanien, 8025
        • Aktiv, inte rekryterande
        • Research Site
      • Barcelona, Catalonia, Spanien, 8035
        • Aktiv, inte rekryterande
        • Research Site
      • Barcelona, Catalonia, Spanien, 8036
        • Aktiv, inte rekryterande
        • Research Site
      • Granollers, Catalonia, Spanien, 8402
        • Aktiv, inte rekryterande
        • Research Site
      • L'Hospitalet de Llobregat, Catalonia, Spanien, 8908
        • Aktiv, inte rekryterande
        • Research Site
      • Lleida, Catalonia, Spanien, 25198
        • Aktiv, inte rekryterande
        • Research Site
      • Terrassa, Catalonia, Spanien, 8221
        • Aktiv, inte rekryterande
        • Research Site
    • Galicia
      • Ourense, Galicia, Spanien, 32005
        • Rekrytering
        • Research Site
      • Santiago de Compostela, Galicia, Spanien, 15706
        • Aktiv, inte rekryterande
        • Research Site
      • Vigo, Galicia, Spanien, 36312
        • Rekrytering
        • Research Site
    • Madrid
      • Madrid, Madrid, Spanien, 28006
        • Rekrytering
        • Research Site
      • Madrid, Madrid, Spanien, 28031
        • Aktiv, inte rekryterande
        • Research Site
      • Madrid, Madrid, Spanien, 28034
        • Aktiv, inte rekryterande
        • Research Site
      • Madrid, Madrid, Spanien, 28905
        • Aktiv, inte rekryterande
        • Research Site
      • Madrid, Madrid, Spanien, 28911
        • Aktiv, inte rekryterande
        • Research Site
      • Madrid, Madrid, Spanien, 28040
        • Rekrytering
        • Research Site
      • Madrid, Madrid, Spanien, 28041
        • Rekrytering
        • Research Site
      • Madrid, Madrid, Spanien, 28046
        • Rekrytering
        • Research Site
      • Majadahonda, Madrid, Spanien, 28222
        • Aktiv, inte rekryterande
        • Research Site
    • Murcia
      • El Palmar, Murcia, Spanien, 30120
        • Aktiv, inte rekryterande
        • Research Site
      • Murcia, Murcia, Spanien, 30008
        • Rekrytering
        • Research Site
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spanien, 33011
        • Aktiv, inte rekryterande
        • Research Site
    • Valencia
      • Alicante, Valencia, Spanien, 3010
        • Rekrytering
        • Research Site
      • Valencia, Valencia, Spanien, 46010
        • Aktiv, inte rekryterande
        • Research Site
      • Valencia, Valencia, Spanien, 46014
        • Aktiv, inte rekryterande
        • Research Site
      • Valencia, Valencia, Spanien, 46026
        • Aktiv, inte rekryterande
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.

Beskrivning

Inclusion Criteria:

  • Age ≥18 years old at starting acalabrutinib treatment.
  • Diagnosis of CLL.
  • Start of acalabrutinib treatment (index date) as per the CLL SmPC:
  • in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
  • in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).

Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.

  • Informed consent (for alive patients).

Exclusion Criteria:

  • Enrolled in any clinical trial during acalabrutinib treatment.
  • Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: OTHER

Kohorter och interventioner

Grupp / Kohort
Cohort 1

Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression.

Cohort 2

Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
Tidsram: 24 months after treatment initiation (cohort 1).

Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).

In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:

  1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression),
  2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV).
  3. cardiovascular comorbidities (yes/no).
24 months after treatment initiation (cohort 1).
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
Tidsram: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first.

From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
Tidsram: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose.

At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
Tidsram: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose.

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment duration in months (cohorts 1 and 2).
Tidsram: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles.

Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
Tidsram: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).

Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1).

The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time:

PDC (%)=(No.days covered)/(No.days of interest)×100

From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
Tidsram: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
Tidsram: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
Tidsram: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation.

Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available).

Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available).

They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 juli 2023

Primärt slutförande (Beräknad)

31 mars 2029

Avslutad studie (Beräknad)

31 mars 2029

Studieregistreringsdatum

Först inskickad

29 juni 2023

Först inskickad som uppfyllde QC-kriterierna

10 augusti 2023

Första postat (Faktisk)

21 augusti 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Tidsram för IPD-delning

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Kriterier för IPD Sharing Access

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera